# HCA Healthcare, Inc.

**HCA**

NYSE; healthcare; SIC 8062, Services-General Medical & Surgical Hospitals, NEC; CIK 0000860730

# None

### No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $60.7B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: distress |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Feb 10, 2026<br>262 days before the rescan; latest periodic filing 10-Q received Oct 29, 2026 |
| **Last close** | $478.06<br>2026-10-29; market equity $99.9B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 10, 2026*

HCA Healthcare, Inc. is one of the leading health care services companies in the United States. At December 31, 2025, we operated 190 hospitals, comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals. In addition, we operated 121 freestanding ambulatory surgery centers ("ASCs") and 31 freestanding endoscopy centers. Our facilities are located in 19 states and England. The terms "Company," "HCA," "HCA Healthcare," "we," "our" or "us," as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The term "affiliates" means direct and indirect subsidiaries of HCA Healthcare, Inc.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 41.4** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (9.7%) | (6.6%) | 41.4 | 805 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 90.4** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *liabilities and a nearby cover-page share count are required at 2026-09-30* | | | | | |
| Altman Z double-prime | not computable | (0.33) | | | |
| *one or more required annual facts are missing* | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 0.97x | 2.94x | 90.4 | 832 | 2025-12-31 |
| **Growth and financing, sleeve percentile 33.4** | | | | | |
| Revenue growth, three-year compound | 7.9% | 10.1% | 54.6 | 413 | 2025-12-31 |
| Free cash flow growth, three-year compound | 23.1% | 10.9% | 36.8 | 96 | 2025-12-31 |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | 5.0% | 2.1% | 41.2 | 697 | 2025-12-31 |
| Net share issuance, one year | (10.0%) | 2.5% | 0.9 | 633 | 2026-01-31 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-10-29 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (2.5%) | 7.7% | 45 |
| Distance from 52-week high | (12.3%) | (26.6%) | 71 |
| EBIT to enterprise value | not computable | (1.4%) | |
| Free cash flow yield | 7.7% | (0.9%) | 89 |
| Book value to price | (0.08) | 0.27 | 8 |
| Sales to price | 0.76 | 0.30 | 79 |
| Composite equity issuance, five years | (53.4%) | 20.5% | 1 |
| Relative strength against the sector, log excess return | (0.24) | (0.14) | 45 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | pass |
| Gross margin improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Asset turnover improved | pass |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $908.0M |
| Operating cash flow, four quarters | $11.2B |
| Months of runway | not finite |
| Days since last periodic filing | 1 (10-Q received Oct 29, 2026) |
| Median daily dollar volume, 63 sessions | $509.0M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | $6.8B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $12.6B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 3 | assets | us-gaap:Assets | $60.7B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 4 | assets | us-gaap:Assets | $59.5B | 2024-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 5 | current assets | us-gaap:AssetsCurrent | $15.8B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $16.4B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 7 | revenue | us-gaap:Revenues | $75.6B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 8 | revenue | us-gaap:Revenues | $70.6B | 2024-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 9 | revenue | us-gaap:Revenues | $65.0B | 2023-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 10 | revenue | us-gaap:Revenues | $60.2B | 2022-12-31 | 2025-02-14 | 10-K | 25-020134 |
| 11 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.9B | 2025-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 12 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $10.5B | 2024-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.9B | 2024-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $9.4B | 2023-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.7B | 2023-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $8.5B | 2022-12-31 | 2025-02-14 | 10-K | 25-020134 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $4.4B | 2022-12-31 | 2025-02-14 | 10-K | 25-020134 |
| 18 | assets | us-gaap:Assets | $56.2B | 2023-12-31 | 2026-02-10 | 10-K | 26-044769 |
| 19 | assets | us-gaap:Assets | $52.4B | 2022-12-31 | 2025-02-14 | 10-K | 25-020134 |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 223,622,200 | 2026-01-31 | 2026-02-10 | 10-K | 26-044769 |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 248,341,900 | 2025-01-31 | 2025-02-14 | 10-K | 25-020134 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.